Open AccessClinical value of soluble urokinase-type plasminogen activator receptor (SuPAR) as a biomarker of disease activity in Behcet’s disease
Author(s) -
Amal Rizk,
Walaa Abdelfattah,
Arwa Al-Shaarawy,
Nora Y. Elsaid
Publication year - 2021
Publication title -
revmatologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.1
H-Index - 15
eISSN - 2738-831X
pISSN - 1310-0505
DOI - 10.35465/29.4.2021.pp47-52
Subject(s) - supar , behcet's disease , medicine , biomarker , disease , plasminogen activator , pathogenesis , urokinase , urokinase receptor , immunology , gastroenterology , biology , biochemistry
Background: Behçet's disease (BD) is a chronic multisystemic vasculitic disease of unknown pathogenesis. Diagnosis and disease activity measurement has always been a challenge. Soluble urokinase plasminogen activator receptor (suPAR) is showing an increased utility as a promising diagnostic and prognostic inflammatory biomarker in different systemic inflammatory disorders. Objectives: To study the clinical value of plasma Soluble urokinase plasminogen activator receptor (suPAR) in patients with Behçet's disease, and if it can be used as a measure to disease activity. Methods: According to the International Criteria for Behcet's Disease (ICBD), fifty adult Behçet's disease patients were enrolled in the study, and forty healthy adult subjects were included in a case-control study. An enzyme-linked immunosorbent assay was used to obtain quantitative data. Results: The suPAR level was not statistically different between the patients with BD patients and the controls. No correlation was found between suPAR levels and disease activity (BDFAC). Conclusion: Very few studies analyzed the clinical value of suPAR level in patients with BD and its correlation with disease activity. Our results show that suPAR does not seem to play a role in the disease mechanism of BD.